Investors and Partners

Investors and Partners2018-05-04T21:28:10+00:00


Previously, no stratification test existed for Triple Negative Breast Cancer (TNBC) Patients. The lack of a stratification test meant that all Triple Negative Breast Cancer Patients received the same standard-of-care chemotherapy.

  • That means roughly 67% of patients endured 4 to 6 months of life-disrupting, ineffective standard-of-care chemotherapy.

  • That means Oncologists had to deliver those confidence-shattering results roughly 67% of the time.

  • That means insurance companies had to pay unnecessary treatment costs.

Roughly 20% of Breast Cancer cases in the United States are diagnosed as TNBC. TNBC refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) and Her2/neu. In 2018, it is estimated there will be 266,120 new Breast Cancer cases in the U.S. That means that 53,224 cases will be diagnosed as TNBC, or roughly 146 new TNBC cases per day. Thus, a stratification assay to help Oncologist and Patients understand which treatment will be the most effective and efficient for their personalized case is a critical unmet need.

Since developing the BA100 Triple Negative Breast Cancer Stratification Test, we now know which 67% of patients will not achieve a complete response to the standard-of-care chemotherapy. This new information allows for better-informed treatment decisions.

BA100 is now available to select Oncologists throughout the United States as we begin to bring the test to the Oncologists around the world. To request our investor material, please click the button below.

Request Investor Material
See Publications and News

Trusted Partners

We are standing on the shoulders of giants. Without the support of these amazing partners, we would not have been able to bring BA100 – the worlds first and only triple negative breast cancer stratification test – to the world. Thank you!